Use este identificador para citar ou linkar para este item: http://sgc.anlis.gob.ar/handle/123456789/287
Título: Genomic signatures of the haarlem lineage of Mycobacterium tuberculosis: implications of strain genetic variation in drug and vaccine development
Autor(es): Cubillos-Ruiz, Andrés 
Sandoval, Andrea 
Ritacco, Viviana 
López, Beatriz 
Robledo, Jaime 
Correa, Nidia 
Hernandez-Neuta, Iván 
Zambrano, Maria Mercedes 
Del Portillo, Patricia 
Palavras-chave: Mycobacterium tuberculosis;Tuberculosis;Mutagénesis Insercional;Antituberculosos;Polimorfismo Genético
Data do documento: 2010
Descrição: 
Tuberculosis is the world’s leading cause of death due to a single infectious agent, and efforts aimed at its control require a better understanding of host, environmental, and bacterial factors that govern disease outcome. Growing evidence indicates that certain Mycobacterium tuberculosis strains of distinct phylogeographic lineages elicit unique immunopathological events. However, identifying the genetic basis of these phenotypic peculiarities has proven difficult. Here we report the presence of six large sequence polymorphisms which, together with two single-nucleotide changes previously described by our group, consistently differentiate Haarlem strains from the remaining M. tuberculosis lineages. The six newly found Haarlem-specific genetic events are four deletions, which altogether involve more than 13 kb, and two intragenic insertions of the element IS6110. The absence of the genes involved in these polymorphisms could have an important physiological impact on Haarlem strains, i.e., by affecting key genes, such as Rv1354c and cyp121, which have been recently proposed as plausible drug targets. These lineage-specific polymorphisms can serve as genetic markers for the rapid PCR identification of Haarlem strains, providing a useful tool for strain surveillance and molecular epidemiology studies. Strain variability such as that described here underscores the need for the definition of a core set of essential genes in M. tuberculosis that are ubiquitously present in all circulating lineages, as a requirement in the development of effective antituberculosis drugs and vaccines.

Fil: Cubillos-Ruiz, Andrés. Corporación Corpogen; Colombia.

Fil: Sandoval, Andrea. Corporación Corpogen; Colombia.

Fil: Ritacco, Viviana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.

Fil: López, Beatriz. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.

Fil: Robledo, Jaime. Universidad Pontificia Bolivariana. Corporación para Investigaciones Biológicas; Colombia.

Fil: Correa, Nidia. Universidad Pontificia Bolivariana. Corporación para Investigaciones Biológicas; Colombia.

Fil: Hernandez-Neuta, Iván. Corporación Corpogen; Colombia.

Fil: Zambrano, Maria Mercedes. Corporación Corpogen; Colombia.

Fil: Del Portillo, Patricia. Corporación Corpogen; Colombia.
URI: http://jcm.asm.org/content/48/10/3614.full.pdf+html
http://sgc.anlis.gob.ar/handle/123456789/287
ISSN: 1098-660X
Direitos: info:eu-repo/semantics/openAccess
Aparece nas Coleções:snrd
Publicaciones INEI

Arquivos neste item:
Arquivo Descrição TamanhoFormato
JournalofClinicalMicrobiology,2010,48(10),3614–3623..pdfPDF1.34 MBAdobe PDFMiniatura
Ver/Aberto
Mostrar registro completo do item

Visualização de página

71
Checado em 02/05/2024

Download(s)

54
Checado em 02/05/2024

Google ScholarTM

Checar


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.